Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Illinois at Chicago
Study ID
NCT06919081
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Corneal Epithelial Disorders
  • Persistent Corneal Epithelial Defect

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome — DRUG
    Eye Drops
  • Vehicle Control — OTHER
    Eye Drops

Study Details

In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.

Key Dates

Start date
Aug 1, 2025
Status verified
May 2025
Primary completion
Mar 15, 2026
Completion
Jun 15, 2026

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome
    Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome for Topical Eye Drop
  • Placebo Comparator: Vehicle
    Vehicle (unconditioned media)

Primary Outcome Measure

Improvement of Corneal Epithelial Barrier and/or Integrity (Efficacy Outcome) [ Time Frame: Baseline to Day 56 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Illinois at ChicagoChicagoIllinois60612
Jale Yucel
[email protected]
708-752-6905

Find similar trials in Chicago, IL

By research site
University of Illinois at Chicago· Chicago, IL

Related Studies